Surviving Sepsis Campaign : International Guidelines for Management of Sepsis and Septic Shock: 2016
OBJECTIVE: To provide an update to "Surviving Sepsis Campaign Guidelines for Management of Sepsis and Septic Shock: 2012".
DESIGN: A consensus committee of 55 international experts representing 25 international organizations was convened. Nominal groups were assembled at key international meetings (for those committee members attending the conference). A formal conflict-of-interest (COI) policy was developed at the onset of the process and enforced throughout. A stand-alone meeting was held for all panel members in December 2015. Teleconferences and electronic-based discussion among subgroups and among the entire committee served as an integral part of the development.
METHODS: The panel consisted of five sections: hemodynamics, infection, adjunctive therapies, metabolic, and ventilation. Population, intervention, comparison, and outcomes (PICO) questions were reviewed and updated as needed, and evidence profiles were generated. Each subgroup generated a list of questions, searched for best available evidence, and then followed the principles of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system to assess the quality of evidence from high to very low, and to formulate recommendations as strong or weak, or best practice statement when applicable.
RESULTS: The Surviving Sepsis Guideline panel provided 93 statements on early management and resuscitation of patients with sepsis or septic shock. Overall, 32 were strong recommendations, 39 were weak recommendations, and 18 were best-practice statements. No recommendation was provided for four questions.
CONCLUSIONS: Substantial agreement exists among a large cohort of international experts regarding many strong recommendations for the best care of patients with sepsis. Although a significant number of aspects of care have relatively weak support, evidence-based recommendations regarding the acute management of sepsis and septic shock are the foundation of improved outcomes for these critically ill patients with high mortality.
| Errataetall: |
CommentIn: Eur Respir J. 2018 Jul 11;52(1):. - PMID 29997181 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Intensive care medicine - 43(2017), 3 vom: 19. März, Seite 304-377 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.07.2017 Date Revised 10.04.2022 published: Print-Electronic CommentIn: Eur Respir J. 2018 Jul 11;52(1):. - PMID 29997181 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00134-017-4683-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM268136378 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM268136378 | ||
| 003 | DE-627 | ||
| 005 | 20231224222104.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00134-017-4683-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0893.xml |
| 035 | |a (DE-627)NLM268136378 | ||
| 035 | |a (NLM)28101605 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rhodes, Andrew |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Surviving Sepsis Campaign |b International Guidelines for Management of Sepsis and Septic Shock: 2016 |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.07.2017 | ||
| 500 | |a Date Revised 10.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Eur Respir J. 2018 Jul 11;52(1):. - PMID 29997181 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: To provide an update to "Surviving Sepsis Campaign Guidelines for Management of Sepsis and Septic Shock: 2012" | ||
| 520 | |a DESIGN: A consensus committee of 55 international experts representing 25 international organizations was convened. Nominal groups were assembled at key international meetings (for those committee members attending the conference). A formal conflict-of-interest (COI) policy was developed at the onset of the process and enforced throughout. A stand-alone meeting was held for all panel members in December 2015. Teleconferences and electronic-based discussion among subgroups and among the entire committee served as an integral part of the development | ||
| 520 | |a METHODS: The panel consisted of five sections: hemodynamics, infection, adjunctive therapies, metabolic, and ventilation. Population, intervention, comparison, and outcomes (PICO) questions were reviewed and updated as needed, and evidence profiles were generated. Each subgroup generated a list of questions, searched for best available evidence, and then followed the principles of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system to assess the quality of evidence from high to very low, and to formulate recommendations as strong or weak, or best practice statement when applicable | ||
| 520 | |a RESULTS: The Surviving Sepsis Guideline panel provided 93 statements on early management and resuscitation of patients with sepsis or septic shock. Overall, 32 were strong recommendations, 39 were weak recommendations, and 18 were best-practice statements. No recommendation was provided for four questions | ||
| 520 | |a CONCLUSIONS: Substantial agreement exists among a large cohort of international experts regarding many strong recommendations for the best care of patients with sepsis. Although a significant number of aspects of care have relatively weak support, evidence-based recommendations regarding the acute management of sepsis and septic shock are the foundation of improved outcomes for these critically ill patients with high mortality | ||
| 650 | 4 | |a Consensus Development Conference | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Evidence-based medicine | |
| 650 | 4 | |a Grading of Recommendations Assessment, Development, and Evaluation criteria | |
| 650 | 4 | |a Guidelines | |
| 650 | 4 | |a Infection | |
| 650 | 4 | |a Sepsis | |
| 650 | 4 | |a Sepsis bundles | |
| 650 | 4 | |a Sepsis syndrome | |
| 650 | 4 | |a Septic shock | |
| 650 | 4 | |a Surviving Sepsis Campaign | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Vasoconstrictor Agents |2 NLM | |
| 650 | 7 | |a Calcitonin |2 NLM | |
| 650 | 7 | |a 9007-12-9 |2 NLM | |
| 700 | 1 | |a Evans, Laura E |e verfasserin |4 aut | |
| 700 | 1 | |a Alhazzani, Waleed |e verfasserin |4 aut | |
| 700 | 1 | |a Levy, Mitchell M |e verfasserin |4 aut | |
| 700 | 1 | |a Antonelli, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrer, Ricard |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Anand |e verfasserin |4 aut | |
| 700 | 1 | |a Sevransky, Jonathan E |e verfasserin |4 aut | |
| 700 | 1 | |a Sprung, Charles L |e verfasserin |4 aut | |
| 700 | 1 | |a Nunnally, Mark E |e verfasserin |4 aut | |
| 700 | 1 | |a Rochwerg, Bram |e verfasserin |4 aut | |
| 700 | 1 | |a Rubenfeld, Gordon D |e verfasserin |4 aut | |
| 700 | 1 | |a Angus, Derek C |e verfasserin |4 aut | |
| 700 | 1 | |a Annane, Djillali |e verfasserin |4 aut | |
| 700 | 1 | |a Beale, Richard J |e verfasserin |4 aut | |
| 700 | 1 | |a Bellinghan, Geoffrey J |e verfasserin |4 aut | |
| 700 | 1 | |a Bernard, Gordon R |e verfasserin |4 aut | |
| 700 | 1 | |a Chiche, Jean-Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Coopersmith, Craig |e verfasserin |4 aut | |
| 700 | 1 | |a De Backer, Daniel P |e verfasserin |4 aut | |
| 700 | 1 | |a French, Craig J |e verfasserin |4 aut | |
| 700 | 1 | |a Fujishima, Seitaro |e verfasserin |4 aut | |
| 700 | 1 | |a Gerlach, Herwig |e verfasserin |4 aut | |
| 700 | 1 | |a Hidalgo, Jorge Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Hollenberg, Steven M |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Alan E |e verfasserin |4 aut | |
| 700 | 1 | |a Karnad, Dilip R |e verfasserin |4 aut | |
| 700 | 1 | |a Kleinpell, Ruth M |e verfasserin |4 aut | |
| 700 | 1 | |a Koh, Younsuk |e verfasserin |4 aut | |
| 700 | 1 | |a Lisboa, Thiago Costa |e verfasserin |4 aut | |
| 700 | 1 | |a Machado, Flavia R |e verfasserin |4 aut | |
| 700 | 1 | |a Marini, John J |e verfasserin |4 aut | |
| 700 | 1 | |a Marshall, John C |e verfasserin |4 aut | |
| 700 | 1 | |a Mazuski, John E |e verfasserin |4 aut | |
| 700 | 1 | |a McIntyre, Lauralyn A |e verfasserin |4 aut | |
| 700 | 1 | |a McLean, Anthony S |e verfasserin |4 aut | |
| 700 | 1 | |a Mehta, Sangeeta |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno, Rui P |e verfasserin |4 aut | |
| 700 | 1 | |a Myburgh, John |e verfasserin |4 aut | |
| 700 | 1 | |a Navalesi, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Nishida, Osamu |e verfasserin |4 aut | |
| 700 | 1 | |a Osborn, Tiffany M |e verfasserin |4 aut | |
| 700 | 1 | |a Perner, Anders |e verfasserin |4 aut | |
| 700 | 1 | |a Plunkett, Colleen M |e verfasserin |4 aut | |
| 700 | 1 | |a Ranieri, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Schorr, Christa A |e verfasserin |4 aut | |
| 700 | 1 | |a Seckel, Maureen A |e verfasserin |4 aut | |
| 700 | 1 | |a Seymour, Christopher W |e verfasserin |4 aut | |
| 700 | 1 | |a Shieh, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Shukri, Khalid A |e verfasserin |4 aut | |
| 700 | 1 | |a Simpson, Steven Q |e verfasserin |4 aut | |
| 700 | 1 | |a Singer, Mervyn |e verfasserin |4 aut | |
| 700 | 1 | |a Thompson, B Taylor |e verfasserin |4 aut | |
| 700 | 1 | |a Townsend, Sean R |e verfasserin |4 aut | |
| 700 | 1 | |a Van der Poll, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Vincent, Jean-Louis |e verfasserin |4 aut | |
| 700 | 1 | |a Wiersinga, W Joost |e verfasserin |4 aut | |
| 700 | 1 | |a Zimmerman, Janice L |e verfasserin |4 aut | |
| 700 | 1 | |a Dellinger, R Phillip |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Intensive care medicine |d 1993 |g 43(2017), 3 vom: 19. März, Seite 304-377 |w (DE-627)NLM000234818 |x 1432-1238 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2017 |g number:3 |g day:19 |g month:03 |g pages:304-377 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00134-017-4683-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2017 |e 3 |b 19 |c 03 |h 304-377 | ||